Viridian Therapeutics, Inc. (VRDN)

Market Cap	1.65B
Revenue (ttm)	305,000
Net Income (ttm)	-275.74M
Shares Out	81.67M
EPS (ttm)	-3.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	638,081
Open	19.16
Previous Close	19.08
Day's Range	18.92 - 20.46
52-Week Range	9.90 - 27.20
Beta	0.58
Analysts	Strong Buy
Price Target	38.80 (+92.27%)
Earnings Date	Nov 11, 2025

About VRDN

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: VRDN
• Website: https://www.viridiantherapeutics.com

Financial Performance

In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price target is $38.8, which is an increase of 92.27% from the latest price.

Price Target

$38.8

(92.27% upside)

Analyst Consensus: Strong Buy